AG
ALNY icon

Advisor Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Advisor Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$121K Hold
1,057
– – ﹤0.01% 2792
2019
Q3 		$85K Buy
1,057
+2
+0.2% +$158 ﹤0.01% 3007
2019
Q2 		$77K Sell
1,055
-12
-1% -$921 ﹤0.01% 3057
2019
Q1 		$100K Buy
1,067
+412
+63% +$34.5K ﹤0.01% 2855
2018
Q4 		$48K Sell
655
-21
-3% -$1.61K ﹤0.01% 3208
2018
Q3 		$59K Sell
676
-296
-30% -$29.8K ﹤0.01% 3153
2018
Q2 		$96K Buy
972
+207
+27% +$20.5K ﹤0.01% 2554
2018
Q1 		$92K Buy
765
+460
+151% +$59.3K ﹤0.01% 2613
2017
Q4 		$39K Buy
305
+185
+154% +$23.2K ﹤0.01% 3251
2017
Q3 		$15K Sell
120
-57
-32% -$4.87K ﹤0.01% 3721
2017
Q2 		$14K Buy
177
+50
+39% +$3.19K ﹤0.01% 3719
2017
Q1 		$6K Sell
127
-17
-12% -$786 ﹤0.01% 4013
2016
Q4 		$5K Sell
144
-54
-27% -$2.26K ﹤0.01% 3911
2016
Q3 		$13K Buy
198
+9
+5% +$635 ﹤0.01% 3396
2016
Q2 		$7K Buy
+189
New +$11.9K ﹤0.01% 3626

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Advisor Group's ALNY Position: Q4 2019 in Review

Advisor Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2019 at 1,057 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #2792.

Advisor Group first reported a position in ALNY in Q2 2016 and has held it in 15 quarters since. 315 funds tracked by Wall St. Rank hold ALNY as of Q4 2019.

  • Advisor Group held 1,057 shares of Alnylam Pharmaceuticals worth $121K as of Q4 2019.
  • Advisor Group left its Alnylam Pharmaceuticals share count unchanged in Q4 2019.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2792 holding.
  • Advisor Group first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 315 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.